Hemab Therapeutics raises $135m for prophylactic treatments for bleeding and thrombotic disorders
Hemab Therapeutics, a clinical-stage biotechnology company, has raised $135 million in a Series B financing round for advancing prophylactic treatments for underserved bleeding and thrombotic disorders. The company anticipates using the proceeds from the round to complete an ongoing phase 1/2 study of its bispecific antibody HMB-001 in Glanzmann Thrombasthenia apart from advancing its upcoming […]